Their combined oncogenic effects could explain the significantly shorter survival of gastric cancer patients with high DOK6 tumors (Fig. 2b) and explain why the level of DOK6 expression alone is prognostic independent of TNM stage, currently the only prognosticator in clinical practice. This evidence concerns the gene DOK6 and gastric cancer.